Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00762268 · ClinicalTrials.gov registry record · NA

A Trial of SAMe for Treatment-Resistant Bipolar Depression

A NA study of Depression and Bipolar Disorder, sponsored by Mclean Hospital.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT00762268 is a NA study of Depression and Bipolar Disorder that has completed, run by Mclean Hospital. The registered enrollment target is 23 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00762268, a NA study of Depression and Bipolar Disorder, has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants. The purpose of this study is to examine the effect of these properties on the mood of bipolar subjects with persistent major depression that has been unresponsive to standard pharmacotherapy.

Interventions

  • DRUG Placebo
  • DRUG SAMe

Study Locations (1)

Massachusetts

  • McLean Hospital - Belmont

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2008-09
Est. Completion 2011-09
Phase NA

Sponsor

Mclean Hospital

140 total trials

What the Registry Record Tells You About NCT00762268

The ClinicalTrials.gov registry entry for NCT00762268 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00762268 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00762268 about?

NCT00762268 is a clinical study titled "A Trial of SAMe for Treatment-Resistant Bipolar Depression". S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants. The purpose of this study is to examine the effect of these properties on the mood of bipolar su...

What is the current status of trial NCT00762268?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2008-09. Estimated completion is 2011-09.

What conditions does trial NCT00762268 study?

This clinical trial studies the following conditions: Depression, Bipolar Disorder, Bipolar Depression.

What interventions are being tested in trial NCT00762268?

The interventions under investigation include: Placebo (DRUG), SAMe (DRUG).

Who is sponsoring clinical trial NCT00762268?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00762268 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.